# Empagliflozin Versus Sitagliptin Therapy for Improvement of Myocardial Perfusion Reserve in Diabetic Patients With Coronary Artery Disease

Study · id `cardio:ct-nct03208465` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03208465](<https://clinicaltrials.gov/study/NCT03208465>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03208465

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 100 participants.

## Technical summary

Registry record NCT03208465. Randomized; no masking; primary purpose treatment. Start 2017-08-07 (actual); primary completion 2019-08-01 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 100 participants (enrolled count; ClinicalTrials.gov record NCT03208465, source copy `cardio:ctgov-nct03208465-2019-08-07`, retrieved 2026-10-26)
- Started: 2017-08-07 (actual) (ClinicalTrials.gov record NCT03208465, source copy `cardio:ctgov-nct03208465-2019-08-07`, retrieved 2026-10-26)
- Primary completion: 2019-08-01 (actual) (ClinicalTrials.gov record NCT03208465, source copy `cardio:ctgov-nct03208465-2019-08-07`, retrieved 2026-10-26)
- Completion: 2019-08-01 (actual) (ClinicalTrials.gov record NCT03208465, source copy `cardio:ctgov-nct03208465-2019-08-07`, retrieved 2026-10-26)
- Countries: South Korea (ClinicalTrials.gov record NCT03208465, source copy `cardio:ctgov-nct03208465-2019-08-07`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03208465-2019-08-07`, retrieved 2026-10-26)

## The registry's words

- Brief title: Empagliflozin Versus Sitagliptin Therapy for Improvement of Myocardial Perfusion Reserve in Diabetic Patients With Coronary Artery Disease
- Acronym: ELITE
- Condition: Diabetes Mellitus
- Condition: Coronary Disease
- Intervention (Drug): Empagliflozin
- Intervention (Drug): Sitagliptin
- Lead sponsor: CHEOL WHAN LEE, M.D., Ph.D
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry intervention name matches this record: Empagliflozin (`cardio:empagliflozin`)
- Registry lists this organization as the lead sponsor: CHEOL WHAN LEE, M.D., Ph.D (`cardio:org-cheol-whan-lee-m-d-ph-d`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Comparison of empagliflozin and sitagliptin therapy on myocardial perfusion reserve in diabetic patients with coronary artery disease (`cardio:pubmed-34397987`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 937ecf69ab1464f6c2aadcf5a3dd87407915fc92c0591bdaba3ae8a94fa93de0
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
